BOSNALIJEK #Pain #Sore_throat #HEALTH_CARE
Product description
Pressed lollipops "Lysobakt Duo" are used:
- adults and children over 6 years of age for additional local treatment of moderate sore throat without fever;
as an additional local therapy of diseases:
- oral mucosa and oral cavity: stomatitis (including aphthous), gingivitis;
- throat: adjunctive treatment of laryngitis and pharyngitis;
- in the pre- and postoperative period with tonsillectomy, laryngeal surgery, injuries or abscesses, and after tooth extraction.
Compound
1 hard candy contains (active ingredients):
lysozyme hydrochloride - 20.0 mg, which corresponds to 800,000 OA FIP;
cetylpyridinium chloride - 1.5 mg.
Excipients: sorbitol (E 420), povidone, mint flavor, magnesium stearate.
Contraindications
- hypersensitivity to lysozyme hydrochloride, cetylpyridinium chloride, or to any of the excipients, including allergy to lysozyme or allergy to egg white;
- hypersensitivity to egg white;
- patients with fructose intolerance (due to sorbitol content).
Mode of application
The recommended dose for adults and children over 6 years old is 3-6 lozenges per day. The interval between the use of each next dose of the preparations should be at least 2 hours.
The lollipop should be slowly dissolving, keeping the formed solution in the mouth for a while.
Duration of treatment is 5 days.
Application features
Pregnant
Data on the safety of using the preparation during pregnancy and lactation are limited; therefore, the use of the preparation during pregnancy and lactation should be avoided.
Children
Not prescribed for children under 6 years of age.
Drivers
The preparation does not affect the reaction rate when driving or operating other mechanisms.
Side effects
From the immune system: anaphylactic shock, anaphylactic reactions, Quincke's edema.
Skin disorders: urticaria, rash, itching, erythema multiforme, Stevens-Johnson syndrome.
Storage conditions
Store at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life is 3 years.
$17.99 BUY ONLINE
MORE
No comments:
Post a Comment